The goal of this clinical trial is to compare the safety and effectiveness of Elranatamab versus Lenalidomide in participants with newly diagnosed multiple myeloma who have recently undergone autologous stem cell transplant.
This trial is currently open and accepting patients.
This study is being conducted in three different parts (or arms). The two arms in this study that are open for enrollment are Arms B and C. Arm A is no longer open for patient enrollment. In Arm B, participants will receive Lenalidomide as maintenance therapy, and in Arm C participants will receive Elranatamab as maintenance therapy.
The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.
Phase 3
Enrollment: 760 patients (estimated)
View MoreView all clinical trial locations sorted by state.
Los Angeles, CA
Ann Arbor, MI
Hackensack, NJ
We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.
(888) 828-2206If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.
You can explore trial locations from around the US and connect directly with a trial coordinator.
Find Nearby LocationsYou can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.
Still need help? Send us a message
Learn more about how we work with trial sponsors